Related Experiment Video
Updated: May 26, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Takotsubo cardiomyopathy associated with titration of duloxetine
Kristopher J Selke1, Gaurav Dhar, Joel M Cohn
1Department of Cardiovascular Medicine, Ingham Regional Medical Center/Michigan State University, Lansing, Michigan 48910, USA. selkek@msu.edu
Insights
This case report highlights a potential link between duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), and takotsubo cardiomyopathy. Discontinuation of the medication led to full recovery of heart function.
Area of Science:
- Cardiology
- Pharmacology
- Neuroscience
Background:
- Takotsubo cardiomyopathy involves temporary left ventricular dysfunction, mimicking myocardial infarction without coronary blockages.
- It's often triggered by stress-induced catecholamine surges, causing vasospasm or direct heart injury.
Observation:
- A 59-year-old woman developed takotsubo cardiomyopathy during duloxetine titration.
- Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases catecholamine levels.
Findings:
- The patient's takotsubo cardiomyopathy resolved completely within one month after discontinuing duloxetine.
- This suggests a possible temporal association between SNRI use and the condition.
Implications:
- Clinicians should consider SNRIs like duloxetine as a potential cause of takotsubo cardiomyopathy.
- Further research is warranted to explore the cardiovascular effects of SNRIs and their role in stress-induced cardiomyopathies.
Abstract:
Takotsubo cardiomyopathy is characterized by transient multisegmental left ventricular dysfunction, dynamic electrocardiographic changes that mimic acute myocardial infarction, and the absence of obstructive coronary disease. Takotsubo cardiomyopathy has been solidly associated with antecedent emotional and physical stressors that trigger catecholamine surges, which lead to coronary vasospasm or direct myocardial injury. Some medications can also cause catecholamine surges, although this phenomenon is not as well described. Duloxetine is a combined serotonin and norepinephrine reuptake inhibitor (SNRI). The basic goal of SNRIs is to increase catecholamine levels in neuronal tissue. However, the increased catecholamine levels may also affect the cardiovascular system.Herein, we report the case of a 59-year-old woman whose takotsubo cardiomyopathy was temporally associated with the titration of duloxetine. The duloxetine therapy was subsequently discontinued, and the patient's left ventricular function recovered completely 1 month after the index event. The purpose of this report is to alert clinicians to a possible association between SNRI medications and takotsubo cardiomyopathy.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy